BRPI0814809A2 - Compostos di(arilamino)arílicos - Google Patents
Compostos di(arilamino)arílicosInfo
- Publication number
- BRPI0814809A2 BRPI0814809A2 BRPI0814809-0A2A BRPI0814809A BRPI0814809A2 BR PI0814809 A2 BRPI0814809 A2 BR PI0814809A2 BR PI0814809 A BRPI0814809 A BR PI0814809A BR PI0814809 A2 BRPI0814809 A2 BR PI0814809A2
- Authority
- BR
- Brazil
- Prior art keywords
- arylamine
- arylic
- compounds
- arylic compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/50—Two nitrogen atoms with a halogen atom attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
- C07D251/70—Other substituted melamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007178795 | 2007-07-06 | ||
| PCT/JP2008/062188 WO2009008371A1 (ja) | 2007-07-06 | 2008-07-04 | ジ（アリールアミノ）アリール化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0814809A2 true BRPI0814809A2 (pt) | 2015-02-03 |
Family
ID=40228543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0814809-0A2A BRPI0814809A2 (pt) | 2007-07-06 | 2008-07-04 | Compostos di(arilamino)arílicos |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8318702B2 (pt) |
| EP (1) | EP2172461A4 (pt) |
| JP (1) | JP5233996B2 (pt) |
| KR (1) | KR101323566B1 (pt) |
| CN (1) | CN101687822B (pt) |
| AU (1) | AU2008273426B2 (pt) |
| BR (1) | BRPI0814809A2 (pt) |
| CA (1) | CA2692611A1 (pt) |
| MX (1) | MX2009013625A (pt) |
| RU (1) | RU2463299C2 (pt) |
| TW (1) | TWI389893B (pt) |
| WO (1) | WO2009008371A1 (pt) |
| ZA (1) | ZA200908305B (pt) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6587781B2 (en) | 2000-08-28 | 2003-07-01 | Estimotion, Inc. | Method and system for modeling and processing vehicular traffic data and information and applying thereof |
| US7620402B2 (en) | 2004-07-09 | 2009-11-17 | Itis Uk Limited | System and method for geographically locating a mobile device |
| CA2598893C (en) | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| MX353308B (es) | 2008-05-21 | 2018-01-08 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| US9908884B2 (en) | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
| LT3009428T (lt) | 2009-05-08 | 2018-04-10 | Astellas Pharma Inc. | Diamino heterociklinis karboksamido junginys |
| ES2575084T3 (es) | 2009-06-10 | 2016-06-24 | Chugai Seiyaku Kabushiki Kaisha | Compuesto tetracíclico |
| EP2581370A4 (en) * | 2010-05-18 | 2013-10-16 | Astellas Pharma Inc | CRYSTALS OF A DI (ARYLAMINO) ARYL CONNECTION |
| CN102260263A (zh) * | 2010-05-26 | 2011-11-30 | 四川大学 | 一类二苯胺基嘌呤衍生物及制备方法和医药用途 |
| US20120101108A1 (en) | 2010-08-06 | 2012-04-26 | Cell Signaling Technology, Inc. | Anaplastic Lymphoma Kinase In Kidney Cancer |
| WO2012023138A2 (en) * | 2010-08-18 | 2012-02-23 | Technion Research And Development Foundation Ltd. | Volatile organic compounds for detecting cell dysplasia and genetic alterations associated with lung cancer |
| CN103052386B (zh) | 2010-08-20 | 2016-03-02 | 中外制药株式会社 | 含有四环化合物的组合物 |
| WO2012051587A1 (en) * | 2010-10-14 | 2012-04-19 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in egfr-driven cancers |
| JP2012153674A (ja) | 2011-01-28 | 2012-08-16 | Astellas Pharma Inc | ジ（アリールアミノ）アリール化合物の製造方法及びその合成中間体 |
| WO2012135641A2 (en) | 2011-03-30 | 2012-10-04 | H. Lee Moffitt Cancer Center And Research Institute | Aurora kinase inhibitors and methods of making and using thereof |
| EP2704572B1 (en) | 2011-05-04 | 2015-12-30 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| CN102389430B (zh) * | 2011-09-07 | 2013-08-28 | 苏州大学 | 一种小分子化合物在制备抗肺癌药物中的应用 |
| WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| CN105796569A (zh) * | 2012-09-10 | 2016-07-27 | 杨子娇 | 化合物在制备防治青光眼病的药物中的用途 |
| CN103655566B (zh) * | 2012-09-10 | 2016-12-21 | 杨子娇 | 化合物在制备防治青光眼病的药物中的用途 |
| MY170904A (en) | 2012-09-25 | 2019-09-13 | Chugai Pharmaceutical Co Ltd | Ret inhibitor |
| CN104854101B (zh) * | 2012-11-06 | 2018-05-01 | 上海复尚慧创医药研究有限公司 | Alk激酶抑制剂 |
| JP2016509045A (ja) | 2013-02-22 | 2016-03-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんを治療し、薬剤耐性を防止する方法 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| BR112016005199B1 (pt) | 2013-08-23 | 2022-02-22 | Neupharma, Inc | Certos compostos químicos, composições, e métodos |
| CN104458677A (zh) * | 2013-09-12 | 2015-03-25 | 中国药科大学 | 一种筛选间变性淋巴瘤激酶抑制剂高通量筛选方法 |
| CN104458669A (zh) * | 2013-09-12 | 2015-03-25 | 中国药科大学 | 一种筛选蛋白激酶a抑制剂高通量筛选方法 |
| CN104458670A (zh) * | 2013-09-12 | 2015-03-25 | 中国药科大学 | 一种筛选血管生成素2受体激酶抑制剂高通量筛选方法 |
| JP6873698B2 (ja) | 2014-04-25 | 2021-05-19 | 中外製薬株式会社 | ４環性化合物の新規結晶 |
| TWI831128B (zh) | 2014-04-25 | 2024-02-01 | 日商中外製藥股份有限公司 | 以高用量含有４環性化合物的製劑 |
| CN105330698B (zh) * | 2014-07-04 | 2019-05-28 | 齐鲁制药有限公司 | 螺环芳基磷氧化物和硫化物 |
| JP6487527B2 (ja) * | 2014-07-04 | 2019-03-20 | チル ファーマシューティカル カンパニー リミテッド | スピロ環アリールリン酸化物及びアリールリン硫化物（ｓｐｉｒｏｃｙｃｌｉｃ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｏｘｉｄｅ ａｎｄ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｓｕｌｆｉｄｅ） |
| WO2016022460A1 (en) * | 2014-08-03 | 2016-02-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Potent dual brd4-kinase inhibitors as cancer therapeutics |
| TWI803187B (zh) | 2014-08-08 | 2023-05-21 | 日商中外製藥股份有限公司 | 包含４環性化合物的非晶質體之固體分散體及製劑 |
| KR102584344B1 (ko) | 2015-01-16 | 2023-09-27 | 추가이 세이야쿠 가부시키가이샤 | 병용 의약 |
| CN106008503B (zh) * | 2015-03-31 | 2020-09-01 | 齐鲁制药有限公司 | 螺环芳基砜作为蛋白激酶抑制剂 |
| CN106146478B (zh) * | 2015-04-10 | 2019-07-16 | 海南轩竹医药科技有限公司 | 三嗪衍生物类间变性淋巴瘤激酶抑制剂 |
| WO2017066428A1 (en) | 2015-10-13 | 2017-04-20 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Brd4-kinase inhibitors as cancer therapeutics |
| RU2607371C1 (ru) * | 2015-11-19 | 2017-01-10 | Закрытое акционерное общество "Р-Фарм"(ЗАО "Р-Фарм") | Замещенные N2-(4-амино-2-метоксифенил)-N4-[2-(диметилфосфорил)-фенил]-5-хлор-пиримидин-2,4-диамины в качестве модуляторов ALK и EGFR, предназначенные для лечения рака |
| CN106928275B (zh) * | 2015-12-29 | 2020-10-02 | 齐鲁制药有限公司 | 螺环胺类芳基磷氧化合物的制备方法及其中间体和晶型 |
| JP6816763B2 (ja) | 2016-03-31 | 2021-01-20 | 住友化学株式会社 | 複素環化合物 |
| WO2018035061A1 (en) | 2016-08-15 | 2018-02-22 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| CN107011266B (zh) * | 2017-05-02 | 2023-04-14 | 中国人民解放军第二军医大学 | 苯并吲唑类衍生物的前药及其制备方法、应用 |
| RU2654695C1 (ru) * | 2017-07-28 | 2018-05-22 | Акционерное Общество "Р-Фарм" (Ао "Р-Фарм") | 8-(1-{ 4-{ (5-Хлор-4-{ (2-(диметилфосфорил)фенил)амино} пиримидин-2-ил)амино)-3-метоксифенил} пиперидин-4-ил)-1-метил-1,8-диазаспиро(4.5)декан-2-он и его фармацевтически приемлемые соли в качестве модулятора ALK и EGER, предназначенные для лечения рака |
| JP7085242B2 (ja) * | 2017-12-21 | 2022-06-16 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | キナーゼ活性を阻害するためのアリールホスフィンオキシド |
| WO2019196812A1 (zh) * | 2018-04-09 | 2019-10-17 | 上海科技大学 | 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用 |
| BR112020025499A2 (pt) | 2018-06-29 | 2021-03-09 | Chugai Seiyaku Kabushiki Kaisha | Composição farmacêutica que compreende agente básico pouco solúvel |
| PL3848361T3 (pl) | 2018-09-04 | 2025-07-07 | Chugai Seiyaku Kabushiki Kaisha | Sposób wytwarzania związku tetracyklicznego |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| WO2020147702A1 (en) * | 2019-01-17 | 2020-07-23 | Betta Pharmaceuticals Co., Ltd | Egfr inhibitors, compositions and methods thereof |
| CN111606883B (zh) | 2019-02-25 | 2023-05-09 | 上海科技大学 | 基于戊二酰亚胺骨架的含硫化合物及其应用 |
| CN109776513A (zh) * | 2019-03-18 | 2019-05-21 | 福建省医学科学研究院 | 一类4-苯基-1,3,5-三嗪-2-胺类抗肿瘤化合物及其制备方法 |
| CN110256429B (zh) * | 2019-06-17 | 2021-06-22 | 广东药科大学 | 一种具有螺环结构的氨基嘧啶类化合物及其制备方法和应用 |
| WO2021023233A1 (zh) | 2019-08-05 | 2021-02-11 | 上海科技大学 | Egfr蛋白降解剂及其抗肿瘤应用 |
| CN115667251A (zh) * | 2021-05-17 | 2023-01-31 | 株式会社沃若诺伊生物 | 杂芳基衍生物化合物、及其用途 |
| CN114805223B (zh) * | 2022-05-30 | 2023-05-09 | 自贡市第四人民医院(自贡市急救中心) | 一种用于抑制egfr的2，4-二取代喹唑啉类化合物及制备方法及应用 |
| CN116283915A (zh) * | 2022-09-08 | 2023-06-23 | 中国科学院生物物理研究所 | 促进致癌融合蛋白EML4-ALK通过泛素化途径降解的小分子化合物dEALK1 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997020822A1 (en) * | 1995-12-01 | 1997-06-12 | Novartis Ag | Quinazolin-2,4-diazirines as npy receptor antagonist |
| MXPA02003436A (es) | 1999-10-07 | 2002-08-20 | Amgen Inc | Inhibidores de triazina cinasa. |
| WO2003055866A1 (en) * | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| RU2343148C2 (ru) * | 2002-02-01 | 2009-01-10 | Райджел Фармасьютикалз, Инк | Соединения 2,4-пиримидиндиаминов и их применение |
| KR100875362B1 (ko) * | 2002-02-05 | 2008-12-22 | 아스텔라스세이야쿠 가부시키가이샤 | 2,4,6-트리아미노-1,3,5-트리아진 유도체 |
| AU2003209077A1 (en) | 2002-02-08 | 2003-09-02 | Smithkline Beecham Corporation | Pyrimidine compounds |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| US7288529B2 (en) | 2003-04-24 | 2007-10-30 | New York University | ALK protein tyrosine kinase, cells and methods embodying and using same |
| PT1660458E (pt) | 2003-08-15 | 2012-04-27 | Novartis Ag | 2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário |
| GB0321710D0 (en) * | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
| US20070105839A1 (en) | 2003-09-18 | 2007-05-10 | Patricia Imbach | 2, 4-Di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
| GB0419160D0 (en) | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| GB0419161D0 (en) | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| WO2007059300A2 (en) | 2005-11-15 | 2007-05-24 | Medimmune, Inc. | Anti-alk antagonist and agonist antibodies and uses thereof |
| WO2007095812A1 (en) | 2006-02-27 | 2007-08-30 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Substituted [1,3,5] triazine compounds, their processes for preparation and uses thereof |
| PT2450437T (pt) | 2006-04-14 | 2017-08-25 | Cell Signaling Technology Inc | Defeitos de genes e cinase alk mutante em tumores sólidos humanos |
| ES2458497T3 (es) | 2006-04-14 | 2014-05-05 | Cell Signaling Technology, Inc. | Defectos de genes y quinasa ALK mutante en tumores sólidos humanos |
| CA2598893C (en) | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| EP1914240B1 (en) | 2006-10-11 | 2009-12-02 | Astellas Pharma Inc. | EML4-ALK fusion gene |
| ES2555803T3 (es) | 2006-10-23 | 2016-01-08 | Cephalon, Inc. | Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met |
| EA017405B9 (ru) | 2006-12-08 | 2014-05-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов протеинкиназы |
| ES2424977T3 (es) | 2007-08-08 | 2013-10-10 | Glaxosmithkline Intellectual Property Development Limited | Derivados de 2-[(2-{fenilamino}-1H-pirrolo[2,3-D]pirimidin-4-il)amino]benzamida como inhibidores de IGF-1R para el tratamiento del cáncer |
| AU2008296479A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
| WO2009054939A2 (en) | 2007-10-19 | 2009-04-30 | Cell Signaling Technology, Inc. | Cancer classification and methods of use |
| MX2010010968A (es) | 2008-04-07 | 2010-10-26 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa de proteina. |
| AU2009233963B2 (en) | 2008-04-07 | 2011-10-06 | Irm Llc | Compounds and compositions as kinase inhibitors |
| MX353308B (es) | 2008-05-21 | 2018-01-08 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
-
2008
- 2008-07-03 TW TW097125119A patent/TWI389893B/zh not_active IP Right Cessation
- 2008-07-04 JP JP2009522627A patent/JP5233996B2/ja not_active Expired - Fee Related
- 2008-07-04 EP EP08777903A patent/EP2172461A4/en not_active Withdrawn
- 2008-07-04 AU AU2008273426A patent/AU2008273426B2/en not_active Ceased
- 2008-07-04 KR KR1020097026439A patent/KR101323566B1/ko not_active Expired - Fee Related
- 2008-07-04 MX MX2009013625A patent/MX2009013625A/es active IP Right Grant
- 2008-07-04 CA CA 2692611 patent/CA2692611A1/en not_active Abandoned
- 2008-07-04 CN CN2008800236055A patent/CN101687822B/zh not_active Expired - Fee Related
- 2008-07-04 WO PCT/JP2008/062188 patent/WO2009008371A1/ja not_active Ceased
- 2008-07-04 US US12/448,759 patent/US8318702B2/en not_active Expired - Fee Related
- 2008-07-04 BR BRPI0814809-0A2A patent/BRPI0814809A2/pt not_active IP Right Cessation
- 2008-07-04 RU RU2010103969/04A patent/RU2463299C2/ru not_active IP Right Cessation
-
2009
- 2009-11-24 ZA ZA2009/08305A patent/ZA200908305B/en unknown
-
2012
- 2012-09-14 US US13/618,732 patent/US20130096100A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009008371A1 (ja) | 2009-01-15 |
| JPWO2009008371A1 (ja) | 2010-09-09 |
| KR20100028563A (ko) | 2010-03-12 |
| JP5233996B2 (ja) | 2013-07-10 |
| TW200918508A (en) | 2009-05-01 |
| CN101687822A (zh) | 2010-03-31 |
| KR101323566B1 (ko) | 2013-10-29 |
| EP2172461A4 (en) | 2011-06-08 |
| EP2172461A1 (en) | 2010-04-07 |
| AU2008273426A1 (en) | 2009-01-15 |
| ZA200908305B (en) | 2011-02-23 |
| CN101687822B (zh) | 2012-11-07 |
| RU2463299C2 (ru) | 2012-10-10 |
| TWI389893B (zh) | 2013-03-21 |
| US8318702B2 (en) | 2012-11-27 |
| US20130096100A1 (en) | 2013-04-18 |
| RU2010103969A (ru) | 2011-08-20 |
| US20100099658A1 (en) | 2010-04-22 |
| AU2008273426B2 (en) | 2012-11-08 |
| CA2692611A1 (en) | 2009-01-15 |
| MX2009013625A (es) | 2010-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0814809A2 (pt) | Compostos di(arilamino)arílicos | |
| LTPA2020501I1 (lt) | Pakeistieji enaminokarbonilo junginiai | |
| EP2199282A4 (en) | amide | |
| DK2185567T3 (da) | Substituerede bicyclolactam-forbindelser | |
| BRPI0813500A2 (pt) | Compostos antivirais | |
| BRPI0821086A2 (pt) | Compostos inseticidas | |
| LU92600I2 (fr) | Sovaldi (sofosbuvir) | |
| EP2123654A4 (en) | pyrazolopyrimidine compound | |
| IL198186A (en) | Mphosph1 derived peptide vaccines | |
| EP2170350A4 (en) | SUBSTITUTED IMIDAZOHETEROCYCLES | |
| ATE542825T1 (de) | Substituierte piperidino-dihydrothienopyrimidine | |
| BRPI0820372A2 (pt) | Compostos herbicidas | |
| BRPI0821627A2 (pt) | Compostos químicos | |
| EP1985620A4 (en) | 10a-azalide compound | |
| BRPI0811264A2 (pt) | Compostos | |
| BRPI0814601A2 (pt) | compostos químicos | |
| ATE524477T1 (de) | Aziridinylepothilonverbindungen | |
| EP2210886A4 (en) | PYRIMIDYLINDOLINVERBINDUNG | |
| BRPI0806689A2 (pt) | Compostos químicos 637 | |
| BRPI0809996A2 (pt) | Compostos | |
| BRPI0814424A2 (pt) | Compostos heterociclila | |
| BRPI0814411A2 (pt) | Compostos químicos | |
| BRPI0815181A2 (pt) | Compostos | |
| ATE443056T1 (de) | Substituierte n-sulfonylaminophenylethyl-2- phenoxyacetamidverbindungen | |
| ITFI20050210A1 (it) | Struttura di indumento per autoprotezione |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |